COMMERCIAL POTENTIAL DRIVES STRONG MARKET SUPPORT FOR MS DRUG TREATMENT
KEY POINTS
- Innate Immunotherapeutics Limited (ASX:IIL) has designed and developed a drug - MIS416 - for use in treating advanced Multiple Sclerosis: Medical biotech company Innate Immunotherapeutics has manufactured a unique proprietary technology that utilises a patient's own immune system to combat the deleterious effects of neuro-degenerative diseases such as Secondary Progressive Multiple Sclerosis (SPMS).
- Currently conducting a Phase 2B drug trial: The Company is undertaking a randomised, double-blind, placebo controlled Phase 2B trial with an enrolled group of 93 patients to determine the efficacy of drug candidate MIS416 drug in treating SPMS. The trial is due for completion by early May 2017 with results expected in August or September.
To view Report please download PDF attached:
Download this document
